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Summary Incancerchemotherapyneutropenia isa common
dose-limiting toxicity. An ability to predict the neutropenic
effectsofcytotoxicagentsbasedonproposedtrialdesignsand
models conditioned on previous studies would be valuable.
The aim of this study was to evaluate the ability of a semi-
mechanistic pharmacokinetic/pharmacodynamic (PK/PD)
model for myelosuppression to predict the neutropenia
observed in Phase I clinical studies, based on parameter
estimates obtained from prior trials. Pharmacokinetic and
neutropenia data from 5 clinical trials for diflomotecan and
from 4 clinical trials for indisulam were used. Data were
analyzed and simulations were performed using the popula-
tion approach with NONMEM VI. Parameter sets were
estimated under the following scenarios: (a) data from each
trial independently, (b) pooled data from all clinical trials and
(c) pooled data from trials performed before the tested trial.
Model performance in each of the scenarios was evaluated by
means of predictive (visual and numerical) checks. The semi-
mechanistic PK/PD model for neutropenia showed adequate
predictive ability for both anti-cancer agents. For diflomote-
can, similar predictions were obtained for the three scenarios.
For indisulam predictions were better when based on data
from the specific study, however when the model parameters
were conditioned on data from trials performed prior to a
specific study, similar predictions of the drug related-
neutropenia profiles and descriptors were obtained as when
all data were used. This work provides further indication that
modeling and simulation tools can be applied in the early
stages of drug development to optimize future trials.
Keywords Neutropenia.Semi-mechanistic model.
Diflomotecan.Indisulam.NONMEM
Introduction
Cytotoxicchemotherapysuppressesthehematopoieticsystem
affecting the host protective mechanisms. Among these
hematological adverse effects, neutropenia is the most serious
and usually the dose limiting toxicity [1]. Several pharmaco-
kinetic/pharmacodynamic (PK/PD) models have been devel-
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One of the more widely used is a semi-mechanistic PK/PD
model developed by Friberg et al. 2002 [7]. This model
describes the time course of myelosuppression after the
administration of anticancer drugs by the use of system and
drug related parameters. Consistency in its system-related
parameters among a wide variety of anti-cancer agents and
regimens has been demonstrated [7–16]. Recently, it has also
been shown that this model could be used to predict the
time-course of myelosuppression in humans, based on data
obtained from experiments in rats [17].
In anti-cancer drug development, the ability to predict
the incidence of neutropenia in subsequent trials, based on
the trial design, and a model conditioned on one or more
previously performed studies would be valuable. It has
been shown for example, that a two-stage design of Phase I
trials, in which data from an initial trial is used to condition
the PK/PD model and to predict a safe starting dose for the
subsequent trials may be applied safely, and is able to
reduce the number of patients included at dose levels below
the recommended dose [18]. As new data are accumulated
during subsequent trials, model parameters can be updated
to potentially provide less biased and more precise
predictions of hematological toxicity.
Real data from the clinical development of two different
anticancer drugs, diflomotecan and indisulam, were used in
the current evaluation. These two drugs were given as
anticancer monotherapy in their respective trials and
therefore the neutropenia observed was a consequence of
the administration of these drugs. Diflomotecan was the
first homocamptothecin to enter clinical trials. Homocam-
potothecins are topoisomerase I inhibitors, that have greater
ability to induce DNA cleavage mediated by topoisomerase
I and a greater ability to stabilize topoisomerase I-DNA
cleavable complexes when compared to the camptothecin-
based topoisomerase I inhibitors [19, 20]. Indisulam is a
cell cycle dependent anticancer drug that inhibits the cell-
cycle at multiple checkpoints. The compound was shown to
suppress the expression of cyclin E and phosphorylation of
cyclin-dependent kinase 2 (CDK2), causing a disruption of
the G1/S transition of the cell cycle [21]. Both compounds
have shown neutropenia as the major dose limiting toxicity
[22–24].
The aim of this study was to evaluate the ability of the
model for hematological toxicity developed by Friberg et al.
2002 [7], to predict neutropenia early in the Phase I program
of new anti-cancer agents, based on data gathered prior to the
trial itself. The current investigation was performed assuming
that Phase I development had occurred sequentially; i.e. trials
investigating new regimens were only started once the
current trial was completed. Model parameter estimates were
obtained from: (a) data from each available trial indepen-
dently, (b) pooled data from all clinical trials available or, (c)
pooled data from the trials performed previously to the tested
trial (Table 1). Using the parameter estimates from each
scenario, absolute neutrophil count (ANC) profiles expected
for each trial were simulated. The simulated profiles from
each scenario were then compared with the observed data,
thus providing a comparison of predictions made from: (a)
model parameters derived only from the trial in question, (b)
model parameters derived from all trials, and (c) model
parameters derived only from those trials preceding the trial
in question.
Methods
Study design and patients
Pharmacokinetic (PK) data and neutrophil counts from
different clinical trials following administration of either
diflomotecan or indisulam were available for the analysis.
All participants provided written informed consent consis-
tent with ICH-GCP (International conference on Harmo-
nisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use—Good Clinical Practice)
and local legislation, once the nature and the intention of
the investigation were fully explained. The studies were
performed in accordance with the Declaration of Helsinki
and were approved by the institutional review board of the
ethics committee at each study site. The characteristics of
the patient population from the five diflomotecan clinical
trials and the four indisulam clinical trials used for the
current analysis are presented in Table 2.
Diflomotecan
Data from five Phase I clinical trials in advanced
malignant tumors including a total of 111 patients were
available. Patients were administered diflomotecan as
intravenous infusion over 20 min on Day 1 (Study 1D)
a n do nd a y s1 ,2 ,3 ,4a n d5( S t u d y4 D )o fa2 1 - d a y
treatment cycle; and on Days 1, 7 and 14 of a 28-day
treatment cycle (Study 2D). Patients in Studies 3D and 5D
r e c e i v e da ni n t r a v e n o u si n f u s i o no nD a y1f o l l o w e db ya n
oral administration given daily during Days 14 to 18.
During the following cycles patients continued to receive
an oral administration daily during five consecutive days
every 21 days. The PK characteristics for intravenous and
oral diflomotecan administrations have been described
previously [10, 23].
Dose levels varied depending on the schedule and the
type of administration (Table 2). Neutrophil counts were
measured in peripheral blood every 3 to 7 days during all
treatment cycles, measuring a total of 2,325 counts for the
five studies.
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Diflomotecan
Characteristic Study 1D Study 2D Study 3D Study 4D Study 5D
Schedule
a inf D 1 inf D 1, 7, 14 inf D1 oral D 14–18 inf D 1–5 inf D1 oral D 14–18
Dose range 1–12 mg/m
2 1–5 mg/m
2 0.9–2.1 mg 0.5–1.5 mg 0.9–2.1 mg
Cycle length 3 weeks 4 weeks 3 weeks 3 weeks 3 weeks
Neutrophil counts 505 252 429 607 532
Demographics
b
Number of patients 24 15 24 30 18
Age (years) 55 (34–73) 52 (29–68) 57 (34–71) 57.5 (35–75) 55.5 (33–70)
Height (cm) 169.5 (152–190) 165 (155–180) 173 (145–189) 169.5 (155–188) 169.5 (158–182)
Weight (Kg) 73 (42–90) 64 (45–101) 71 (51–101) 74 (42–110) 72 (48.5–123)
Body surface area (m
2) 1.85 (1.36–2.17) 1.71 (1.5–2.18) 1.85 (1.59–2.25) 1.87 (1.46–2.39) 1.85 (1.5–2.4)
Basal neutrophil count (x10
9/L) 5.88 (2.23–11.2) 4.64 (2.6–15.22) 5.12 (2.61–12.6) 6.07 (2.6–16.65) 5.19 (1.86–9.87)
Gender
Female 46% 67% 38% 40% 44%
Male 54% 33% 62% 60% 56%
Indisulam
Characteristic Study 1I Study 2I Study 3I Study 4I
Schedule
a 1×2 hr inf 5×daily 2 hr inf 4×weekly 1 hr inf 1×120 hr inf
Dose range 50–1,000 mg/m
2 10–200 mg/m
2/day 40–500 mg/m
2/week 6–200 mg/m
2/day
Cycle length 3 weeks 3 weeks 6 weeks 3 weeks
Neutrophil counts 211 235 453 230
Demographics
b
Number of patients 40 35 42 26
Age (years) 53 (26–69) 53 (27–73) 59 (39–78) 54 (26–64)
Height (cm) 168 (156–203) 167 (152–191) 170 (154–186) 165 (149–178)
Weight (kg) 70 (43–106) 64 (41.0–93.0) 68 (43.4–122) 62 (41.0–89.5)
Body surface area (m
2) 1.80 (1.40–2.30) 1.72 (1.34–2.06) 1.82 (1.43–2.36) 1.70 (1.37–2.06)
Basal neutrophil count (x10
9/L) 5.25 (2.0–16.1) 5.7 (1.78–17.9) 4.9 (2.61–11.8) 4.6 (1.7–12.2)
Gender
Female 50% 72.8% 39.1% 65.5%
Male 50% 37.2% 60.9% 34.5%
a Administration schedule. Inf, infusion; D, day
b Continuous demographic data is shown as median and range within parenthesis
Diflomotecan
Study A. Current Study Data B. All data C. Prior data
1D 1D 1D + 2D + 3D + 4D + 5D NA
2D 2D 1D + 2D + 3D + 4D + 5D 1D
3D 3D 1D + 2D + 3D + 4D + 5D 1D + 2D
4D 4D 1D + 2D + 3D + 4D + 5D 1D + 2D + 3D
5D 5D 1D + 2D + 3D + 4D + 5D 1D + 2D + 3D + 4D
Indisulam
Study A. Current Study Data B. All data C. Prior data
1I 1I 1I + 2I + 3I + 4I NA
2I 2I 1I + 2I + 3I + 4I 1I
3I 3I 1I + 2I + 3I + 4I 1I + 2I
4I 4I 1I + 2I + 3I + 4I 1I + 2I + 3I
Table 1 Data analyzed for each
Scenario to predict the outcome
of the respective studies
NA, Not applicable
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Indisulam has been investigated in a Phase I clinical
program, administered in four different treatment schedules
[22, 25–27] from which PK and neutropenia data from a
total of 150 patients were available. A population PK model
has been developed previously to describe the disposition
of indisulam in all four treatment schedules [28].
In Study 1I, patients were administered indisulam as a
single 2 h infusion every 3 weeks, and in Study 2I
indisulam was given in 5 daily 2-hour infusion, also every
3 weeks. In trial 3I, the regimen consisted of a four times
weekly 1 h infusion, repeated every 6 weeks, while study 4I
consisted of a continuous 120-hour infusion every 3 weeks.
Neutrophil counts were recorded at study entry and at least
once a week and, when feasible, twice a week, up to 2 weeks
after the last infusion of indisulam. When hematological
toxicity occurred, sampling was performed more frequently
according to local guidelines. A total of 1,129 neutrophil
counts were measured for the four studies.
Data analysis
The models were implemented in the non-linear mixed
effects modeling software NONMEM version VI [29], in
which the First Order Conditional Estimation (FOCE)
method with the option INTERACTION was used for
parameter estimation. For each drug the modeling was
performed sequentially using the population modeling
approach. First, the PK model was applied to obtain the
individual parameter estimates for each study, and using
these estimates the time course of ANC was modeled.
Pharmacokinetic model T h et i m ec o u r s eo ft h ed r u g
plasma concentrations for both anticancer agents was
described previously by compartmental models parameter-
ized in apparent volumes of distribution, and distribution
and elimination clearances. The PK model for diflomotecan
consisted of a three compartment model with a first order
elimination [10]. Linear and dose-independent kinetics with
an oral absolute bioavailability of 72±59% of the total
administered dose have been reported for this drug [23].
The indisulam PK model consisted of a three compartment
model with saturable elimination from the central compart-
ment [28]. Additional information on diflomotecan and
indisulam PK can be found in previous publications [10,
23, 28].
Semi-mechanistic model for absolute neutrophil count The
semi-mechanistic model for chemotherapy-induced myelo-
suppression (Fig. 1) previously published by Friberg et al.,
2002 [7] was fitted to the ANC vs. time data. This model
consists of a system dependent and a drug dependent part.
The system dependent part resembles in a simplified
manner the underlying physiological processes determining
the ANC in the circulation: (a) proliferation in a progenitor
cell compartment, (b) maturation without proliferation,
represented in the model by three transit compartments,
(c) elimination from circulation, and (d) homeostatic
regulation: i-iv can be described by the first order rate
constant (kprol), the mean transit time (MTT), the first order
rate constant of elimination from circulation (kcirc), and the
feedback parameter (γ). In addition, Circ0 represents ANC
at baseline. In the original model kProl ¼ kcirc ¼ kTR, where
kTR is the first order rate constant governing the transfer of
immature cells between the transit compartments computed
as n þ 1 ðÞ =MTT, n, being the number of transit compart-
ments included in the model. The drug effect (EDRUG) was
included in the model as kProl   1   EDRUG ðÞ where EDRUG
has the form of Slope × C (linear model), or EMAX  
C= EC50 þ C ðÞ (EMAX model), where C represents the
individual predicted plasma drug concentration, and Slope,
EC50 and EMAX the PD model parameters to be estimated.
In the cases where an EMAX model provided a better fit but
EMAX and/or EC50 could not be estimated precisely, the
following parameterization of the EMAX-model [30] was
used to improve parameter precision:EC50 ¼ EMAX=SLP,
and EDRUG ¼ EMAX   C   SLP= EMAX þ C   SLP ðÞ , where
EMAX and SLP are the parameters to be estimated.
Inter-patient variability (IPV) was modeled exponential-
ly and residual variability was described using an additive
random effect model. Neutrophil data were logarithmically
transformed.
Model selection
The minimum value of the objective function provided by
NONMEM, approximately equal to -2xlog likelihood
(−2LL), was used as a guide during the model develop-
ment. For two nested models a decrease in 3.84 points in -
2LL for an extra parameter was considered significant at
the 5% level.
Modeling strategy
The modeling strategy consisted of two steps: (a) parameter
estimation from the different datasets (see below), and (b)
evaluation of the predictive ability of the model.
(i) Model parameter estimation
Independent analyses were performed for each drug
and model parameter estimates were obtained for each of
the following scenarios: Scenario A, data from each trial
analyzed independently; Scenario B, pooled data from all
available trials, and Scenario C, pooled data from the
trials performed prior to the tested trial.
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diflomotecan (Studies 1D, 2D, 3D, 4D and 5D were
analyzed independently), and for indisulam four datasets
were studied (Studies 1I, 2I, 3I and 4I were analyzed
independently). Scenario B corresponded to one analysis of
pooled data of all the studies for each drug. In Scenario C,
for both diflomotecan and indisulam, it was assumed that
the trials were performed sequentially, i.e. from 1D to 5D,
and from 1I to 4I, thereby leading to four and three steps to
be evaluated, respectively. This approach allowed having
for each trial, from 2D to 5D, for diflomotecan and from 2I
to 4I for indisulam, a set of parameters representing each of
the scenarios be to be studied. A total of nine different
parameter estimate sets for diflomotecan and seven for
indisulam were obtained (Table 1).
(ii) Evaluation of the prediction ability
The ability of theparameter estimates (obtained from each
of the three different scenarios) to describe the observed data
was tested by simulating five hundred datasets having the
same doses, administration schedules and design character-
istics as the original dataset and performing numerical and
visual [31] predictive checks. Five hundred repetitions were
used in the simulation exercise as the use of more
repetitions did not relevantly alter the predicted outcome
measures
Numerical predictive checks
The percentage of patients presenting neutropenia Grade 4
(%G4), and neutropenia Grade 3 or Grade 4 (%G3/4) were
computed for each trial. Thereafter the overall mean and the
95% prediction intervals were calculated for each descriptor
and compared to the same descriptors calculated from the
raw data. This was then represented as a graphic, where
%G4 or %G3/4 observed was plotted against the simulated
%G4 or %G3/4 and its 95% prediction interval.
Visual predictive checks
The area covering the 95% confidence interval of the
predicted median, the 5th and 95th percentiles of the
prediction interval were plotted together with the median,
and the 5th and 95th percentiles of the observed data. If the
model described the data adequately the lines
corresponding to the median, the 5th and 95th percentiles
of the observed data would mainly fall in the area covering
the 95% confidence interval.
For the analysis of simulated data, the R software (http://
cran.r-project.org, version 2.6.0) was used. For the generation
of visual predictive checks PsN (http://psn.sourceforge.net/)
and Xpose version 4 (http://xpose.sourceforge.net/) were
used.
Results
Diflomotecan
(i) Model parameter estimation
For the nine datasets analyzed from the three explored
scenarios the semi-mechanistic PK/PD model of neutrope-
nia described the data adequately. Based on the minimum
value of the objective function observations were consid-
ered best described by the reparameterized EMAX model
(p<0.01) except for the independent analysis of Studies 3D,
4D and 5D, where the drug effect was modeled using a
linear function. The model parameter estimates are pre-
sented in Table 3. The data supported the estimation of IPV
in Circ0, MTT and slope (for linear models) or SLP (for the
reparameterized EMAX models). Inclusion of IPV in the
feedback parameter was not statistically significant (p>
0.05) System- and drug-related parameters were consistent
across the studies. Precision in parameter estimates
increased when the number of pooled patients analyzed
per study increased.
(ii) Evaluation of the prediction ability
Numerical predictive checks
In Fig. 2 the mean values for the observed %G4 and %G3/4
neutropenia are shown against the mean %G4 and % G3/4
Feedback=(Circ0/Circulating cells) Feedback (Circ0/Circulating cells)γ
kProl Prol
kTR
Progenitor Circulating
Ti t 1 Ti t 2 Ti t 3
kTR kTR kTR
Progenitor 
cells
Cc u a t g
neutrophils Transit 1 Transit 2 Transit 3
Edrug drug
k i
Mean transit time (MTT=4/kTR)
kcirc
Mean transit time (MTT=4/kTR)
Fig. 1 Semi-mechanistic model
for neutropenia. Edrug, drug
effect; kprol, 1st order rate
constant of proliferation; kTR,
1st order rate constant of transit;
kcirc, 1st order rate constant
of elimination of circulating
cells; Circ0, basal
neutrophil count; γ, feedback
parameter
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value was within the prediction interval for the %G4
neutropenia for all evaluated situations, whereas for the
%G3/4 neutropenia observations were outside the prediction
interval in only one case i.e Study 4D in Scenario C
(parameters estimates form previous studies were used in
this case). For Study 4-D, in Scenario A and Scenario B the
observations for %G3/4 were within the prediction intervals.
However these two scenarios did not improve considerably
the predictions when compared with Scenario C.
Visual predictive checks
The visual predictive checks presented in Fig. 3 show that
the description of data for each study was similar,
independently of the set of model parameter estimates used
for the simulations. For each study, the areas covering the
95% confidence interval of the predicted median, 5
th and
95
th percentiles were similar in each scenario.
Indisulam
(i) Model parameter estimation
For the seven datasets analyzed from the three explored
scenarios, the EMAX model did not provide significantly better
fit, judged by the value of -2LL (p>0.05) and visual
predictive checks. Therefore, only linear models were
implemented and estimated. As in previous analyses with this
compound [32, 33], the Circ0 parameter was not estimated,
instead observed baseline ANCs were used, thereby assuming
no error in baseline measurement. Different methods of
incorporating baseline with measurement error are available
[34]. However when Circ0 was estimated, no relevant
differences in predictions were observed and the VPCs for
indisulam showed no apparent bias in the description of the
baseline.
Data supported the estimation of IPVin MTTand slope in
all estimations. The feedback parameter, γ could be estimated
with reasonable precision for all scenarios (RSE <10%), and
was between 0.116 and 0.190 (Table 4). The data did not
support the estimation of IPV in the feedback parameter. The
system- and drug-related parameters were consistent across
the studies and the corresponding estimates are listed in
Table 4.
(ii) Evaluation of the prediction ability
Numerical predictive checks
In Fig. 2 (bottom row) the mean values for the observed
%G4 and %G3/4 neutropenia are shown against the mean
%G4 and % G3/4 neutropenia calculated from the
simulations for indisulam. Predicted %G4 and %G3/4 were
best correlated with the observed when the model was
conditioned on data from the specific study only, as all
prediction intervals contained the observed percentages.
Predictions based on all data were comparable to those
obtained using previously accumulated data. The observed
value for the %G4 and the %G3/4 neutropenia was outside
the prediction interval for the %G4 neutropenia for Study 4I
and for the %G3/4 of the Study 3-I, when conditioned on
all or previous data. For these scenarios, the semi-
Table 3 Final model parameters (RSE%) for diflomotecan
Studies Circ0
(× 10
9/L)
IPV
Circ0 (%)
MTT (days) IPV
MTT (%)
Slope
(mL/ng)
IPV
Slope (%)
SLP
(mL/ng)
IPV
SLP (%)
EC50
a EMAX γ Residual
error (%)
b
1D 4.69 (10.5) 36.7 (29) 5.31 (8) 31.1 (37) –– 0.817
(124)
110
(94)
7.55 6.17
(116)
0.142 (8) 61 (26)
2D 5.51 (15.7) 50.3 (41) 5.14 (14) 10.9 (134) –– 1.35 (54) 66 (64) 4.78 6.46 (81) 0.153 (20) 45 (26)
3D 4.98 (8.9) 34.8 (36) 4.08 (14) 23.3 (37) 0.625
(20)
50.2 (78) –– – –0.0855 (16) 51 (24)
4D 6.57 (8.1) 40 (31) 4.53 (9) 22.4 (49) 1.06
(12)
51 (42) –– – – 0.096 (10) 47 (20)
5D 5.27 (8.9) 35.9 (37) 5.06 (13) 25.7 (46) 0.823
(22)
32 (193) –– – –0.0787 (13) 42 (15)
1D, 2D 4.99 (8.4) 42.3 (31) 5.2 (6) 36.1 (27) –– 1.11 (85) 103
(62)
4.94 5.49 (68) 0.142 (6) 56 (23)
1D, 2D,
3D
5.07 (6.2) 38.6 (27) 4.89 (7) 26.3 (27) –– 1.02 (39) 93 (39) 5.22 5.33 (40) 0.123 (10) 55 (17)
1D, 2D,
3D, 4D
5.46 (5.04) 39.4 (21) 4.82 (5) 25.1 (23) –– 1.13 (21) 87 (26) 4.78 5.40 (46) 0.117 (8) 53 (14)
All 5.37 (1.9) 40 (19) 4.91 (5) 25.9 (21) –– 1.07 (17) 82 (25) 5.22 5.59 (27) 0.113 (8) 51 (12)
Parameters are listed together with the coefficient of variation [CV(%)] in parenthesis. Circ0, basal ANC; MTT, maturation mean transit time; γ,
feedback parameter; IPV, inter-patient variability expressed as CV (%).
a Parameter calculated as EC50=EMAX/SLP,
b Implemented as additive error
on the log-scale
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dependency adequately, and the occurrence of toxicity would
have been significantly underestimated or overestimated.
Visual predictive checks
For all studies, model fit was best when the model was
conditioned on data from the specific study alone (Fig. 4).
Model fit was not equally good for the cases where the
model was fitted on all data. However, when fitted on only
previously accumulated data, the model fit was similar to
when all data were used. For Study 4I, studying the
continuous infusion, model misspecification was present
when the model was conditioned on all or previous data:
the observed lower boundary of the 90% prediction interval
was significantly lower than predicted in several consecu-
tive bins. When conditioned on data from the study itself,
the misspecification was less apparent.
Discussion
The predictive ability of the PK/PD neutropenia model was
evaluated for the anticancer drugs diflomotecan and
indisulam. For both drugs simulations showed, visually
and numerically, that a very similar description of data is
achieved when data from all studies was used to condition
the model, compared to the situation when data from the
prior studies only was used. In most cases, such model
performance also corresponded with the description of data
provided by the model conditioned on the specific data of
the study. Although each study had a different dose
administration schedule, and a wide range of doses were
studied throughout all the trials, the approach described
here allowed for predictions based on model parameters
obtained from prior trials. However an interesting fact seen
for both of the drugs was that for Scenario C (use of
previous data) the predictions did not turn out to be better
Fig. 2 Relation between the percentage of Grade 4 or Grade ≥ 3
observed versus the percentage predicted for diflomotecan (top row)
and indisulam (bottom row).Symbols represent the relation between
the observed percentage of patients developing neutropenia (Grade 4
or Grade ≥ 3) and the median of the percentage of patients developing
neutropenia (Grade 4 or Grade ≥ 3) from simulations. Lines represent
the 95% interval of the predicted descriptor
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for Study 4I based on previous data (i.e. Study 1I, 2I and
3I) were not better than predictions for Study 2I based only
on Study 1I. This could be due to a schedule dependency in
the development of toxicity that is not be captured by the
model as Study 4I has a very different schedule (120 h
infusion every 21 days) from the previous schedules tested.
For diflomotecan a similar case was presented, where
percentage of Grade 3/4 neutropenia for Studies 3D and 4D
was not as well predicted as for Study 2I in Scenario C.
The semi-mechanistic model was successfully applied in
all cases for both drugs, and in general precise parameters
were provided. For diflomotecan in most of the cases an
EMAX model fitted data better than a linear model, except
for the low dose studies where it was not possible to fit an
EMAX model. This was most likely due to the fact that these
concentrations would correspond to the linear part of the
response-concentration curve. In these linear models the
difference for the slope parameter of 0.625 to 1.05 mL/ng
(Studies 3D-5D) might be caused by the use of a reduced
model due to the limited range of concentrations in those
particular studies. However, when the EMAX model was
selected the range in the SLP and EMAX parameters was
smaller: 0.82–1.35 mL/ng and 5.33–6.46, respectively. In
the manuscript by Trocóniz et al. [10], data obtained after
administration of higher doses of diflomotecan were
analyzed. Based on the results provided by the current
evaluation where the EMAX model was identified as a better
model than the linear one, the slope estimated in that case
(0.144 mL/ng) should correspond to the upper (less steep)
part of the effect vs concentration relationship.
Although system-related parameters obtained between
studies and the two compounds were consistent, MTT
estimates were in general higher for indisulam than for
diflomotecan. A higher MTT estimate for indisulam in
comparison with other drugs has been reported previously
[9].
The critical aspect in the current approach resides in the
extrapolation capability of model parameter estimates
obtained from a specific study to previously unstudied
schedules. Therefore, it was of importance to study the
model performance when using the model from data not
including the current data of the study (Scenario C). In
general, the visual predictive checks showed that ANC time
profiles obtained for that case were similar to the ones for
the cases where the current study data were taken into
account (Scenarios A and B), indicating that parameter
estimates could be extrapolated. However, and in particular
for Study 4I, the description of the ANC time profile was
considerably better for the case in which only data from the
study was used to condition the model (Scenario A). The
administration schedule of Study 4I consisted of a 5 day
long continuous infusion; all the other studies analyzed had
an infusion duration of 2 h or less. For this study, besides
the large difference in administration schedule, also differ-
ences in the studied patient population may have inflated
the differences in predictions. For instance, Study 4I had
the lowest number of patients included, the highest
percentage female patients, the lowest median weight, and
the lowest median baseline ANCs of all four studies. If only
data from a low number of patients is available, a critical
assessment of predictive ability is difficult, since of those
patients, only a low number of patients will develop grade
3/4 toxicities. Therefore, calculation of confidence intervals
of observed ANC counts for such a study is sensitive to the
inclusion of a few outlying patients.
However, for both drugs, using data of all studies (Scenario
B) provided very similar predictions as using only data from
prior studies (Scenario C). For indisulam, predicting neutro-
peniatoxicitybasedondatafrompreviousanalyseshadshown
tobeonlymoderatelyaccurate.Predictioncouldhowever only
be improved when data from the specific study were used.
Table 4 Final model parameters (RSE%) for indisulam
Studies MTT (days) IPV MTT (%) Slope (mL/ng) IPV Slope (%) γ Residual error (%)
1I 6.37 (2) 27.6 (11) 0.0242 (4) 38.6 (26) 0.167 (10) 42 (14)
2I 7.11 (2) 24.1 (18) 0.0279 (5) 55.2 (41) 0.190 (7) 34 (14)
3I 8.78 (1) 30.6 (31) 0.0176 (5) 73 (28) 0.152 (7) 35 (1)
4I 5.06 (2) 36.7 (22) 0.0156 (6) 110 (27) 0.116 (7) 43 (13)
1I, 2I 6.63 (1) 26.8 (10) 0.0252 (3) 47.8 (23) 0.177 (7) 38 (10)
1I, 2I, 3I 7.26 (<1) 22.7 (9) 0.0219 (<1) 55.0 (17) 0.16 (1) 37 (8)
All studies 6.90 (1) 23.5 (9) 0.0211 (1) 59.0 (14) 0.152 (2) 38 (7)
Parameters are listed together with the coefficient of variation [CV(%)] in parenthesis. MTT, maturation mean transit time; γ, feedback parameter;
IPV, inter-patient variability expressed as CV (%)
Fig. 3 Neutrophil count (logarithm) vs time profile after the
administration of diflomotecan for the different studies. Median (solid
line) and 95th and 5th percentiles (dashed line) of the observations.
Dark gray areas cover the 90% CI of the median and light grey areas
cover the 90%CI of the 95th and the 5th percentiles of the simulated
profiles
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Fig. 4 Neutrophil count (logarithm) vs time profile after the
administration of indisulam for the different studies. Median (solid
line), 95th and 5th percentiles (dashed line) of the observations. Dark
gray areas cover the 95% CI of the median and light grey areas cover
the 95% CI of the 95th and the 5th percentile of the simulated profiles
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was also compared for their ability to predict clinically
relevant descriptors, i.e. the incidence of Grade 3 or Grade 4
neutropenia. Therefore, the percentage of patients developing
either Grade 4 neutropenia, or Grade 3 neutropenia or higher,
was calculated for both the observed data and the simulated
data.
It could be expected that the percentage of neutropenia
for a specific study would be better predicted by the model
conditioned on the data from that specific study. This
means that the left panels in Fig. 2 would present the best
relationship between observed and predicted data. For some
studies however, very similar predictions were seen
regardless the set of model parameters used in the
simulation (very similar predictions in all panels).
Predictions were more accurate for diflomotecan than for
indisulam, especially for the % G4 neutropenia. A possible
explanation for this result may be that in the diflomotecan
trials a higher percentage of patients experienced neutrope-
nia than in indisulam trials (Fig. 2), resulting in a better
characterized dose response relationship.
Previous studies have already shown that estimated
system-related model parameters are consistent across
anti-cancer agents [7–16]. Furthermore, the predictive
ability of this model has been also explored before in (i) a
development of a tool that would be able to predict
hematological toxicity in subsequent clinical trials, based
on the study design and a model conditioned on one or
more previously performed trials [18], and also in (ii) a
method for interspecies scaling where time course of
myelosuppression was predicted based on rat data [17],
showing in both cases promising results. Further studies
will have to verify if the same predictive ability applies to
dose escalation studies.
Assuming that the Phase I development programs of
studied drugs were performed sequentially, the current
analysis explored the ability of the currently most used
semi-mechanistic model of neutropenia to predict hematolog-
icaleffects in subsequent stages ofthe program,based on data
gathered at earlier stages. The results presented in the current
report are encouraging given the fact that for two drugs with
different mechanism of action, and under very different
dosing schedules, trials performed prior to a specific study
gave a similar insight to the drug related-neutropenia as when
using information from all studies retrospectively. It might be
interesting to expand this research to other scenarios, such as
the use of the PRIOR subroutine in NONMEM to introduce
previous information, or the use of published system
parameters in combination with drug related parameters
estimated from previous studies.
Thisinvestigation provides further indication that modeling
and simulation tools can be applied in the early stage of the
drug development process to optimize future trials. Neverthe-
less, further studies should be done to determine the causes of
the model-misspecification that led to the reduced predictive
ability for some administration schedules.
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